Research
Omalizumab linked to lower reaction burden in alpha-gal syndrome
In a 64-patient case series, no one required epinephrine for an alpha-gal reaction while taking omalizumab, but avoidance remains recommended.

A retrospective case series found that patients with alpha-gal syndrome reported fewer or less severe reactions while taking omalizumab. The study included 64 patients treated for at least 3 months. Before treatment, 53% had required epinephrine for a presumed alpha-gal reaction. None required it for an alpha-gal exposure reaction while taking the drug.
Nearly all patients, 95%, reported meaningful improvement in reaction frequency or severity. During treatment, 20% partially reintroduced mammalian products and 13% fully reintroduced them. The median treatment duration was 23 months. Two patients, 3%, stopped treatment because of an adverse event. The study had no untreated comparison group, and its authors said prospective studies are needed to confirm the findings and determine dosing and treatment duration.


